CDK1 and CDK2 activity is a strong predictor of renal cell carcinoma recurrence.
Hongo F, Takaha N, Oishi M, Ueda T, Nakamura T, Naitoh Y, Naya Y, Kamoi K, Okihara K, Matsushima T, Nakayama S, Ishihara H, Sakai T, Miki T.
Hongo F, et al.
Urol Oncol. 2014 Nov;32(8):1240-6. doi: 10.1016/j.urolonc.2014.05.006. Epub 2014 Nov 14.
Urol Oncol. 2014.
PMID: 25443276
Free article.